US Market Report for MIS Sacroiliac Joint Fusion 2017 - MedCore

US Market Report for MIS Sacroiliac Joint Fusion 2017 - MedCore

  • May 2017 •
  • 453 pages •
  • Report ID: 4895063 •
  • Format: PDF

Studies have shown that over 80% of the population will suffer from lower back pain at some point in their lives.

A majority of these cases can be attributed to two main causes: general factors, such as muscle strain, injury and overuse; and specific spine conditions such as herniated discs, degenerative disc disease (DDD), spondylolisthesis or spinal stenosis. Sacroiliac (SI) joint dysfunction was once thought to be a less common cause for lower back pain. However, recent studies have shown that SI joint dysfunction (SIJD) may be responsible for up to 30% to 35% of lower back pain.

Description
General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions

Sacroiliac (SI) joint dysfunction was once thought to be a less common cause for lower back pain. However, recent studies have shown that SI joint dysfunction (SIJD) may be responsible for up to 30% to 35% of lower back pain. Growth of this spinal treatment has historically been limited by the diagnosis process.

One important factor in the future growth of the sacroiliac joint fusion market is the new information surrounding adjacent segment disease. Following a lumbar fusion procedure, whether it was or was not the primary cause of the low back pain, a significant proportion of patients eventually note discomfort or pain in the low back. This can be attributed to the effects of the lumbar fusion, which leads to heightened levels of stress and motion across the sacroiliac joint.

Previous analyses of this market expected considerably more growth following the reimbursement changes and CPT code changes of 2014 and 2015, respectively. However, the high level of demand for treatment from the suspected backlog of patients did not materialize as many in the industry had hoped. Nevertheless, rapid growth is still expected, driven by increasing awareness and product availability.


Scope
2013-2023